Cargando…

P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough

Gefapixant/AF-219, a selective inhibitor of the P2X3 receptor, is the first new drug other than dextromethorphan to be approved for the treatment of refractory chronic cough (RCC) in nearly 60 years. To date, seven P2X subtypes (P2X1-7) activated by extracellular ATP have been cloned, and subtype se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Wen-Wen, Wang, Si-Yu, Zhang, Yu-Qing, Wang, Yao, Fan, Ying-Zhe, Guo, Chang-Run, Li, Xing-Hua, Lei, Yun-Tao, Wang, Wen-Hui, Yang, Xiao-Na, Hattori, Motoyuki, Li, Chang-Zhu, Wang, Jin, Yu, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research Network of Computational and Structural Biotechnology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014320/ https://www.ncbi.nlm.nih.gov/pubmed/35465163 http://dx.doi.org/10.1016/j.csbj.2022.03.030

Ejemplares similares

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
por: Morice, Alyn H., et al.
Publicado: (2021)

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
por: Chuang, Min-Hsiang, et al.
Publicado: (2023)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough
por: Gupta, Pranav, et al.
Publicado: (2022)

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023)

Efficacy of gefapixant, a P2X(3) antagonist, for lung cancer-related cough: a case report
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Chronic cough relief by allosteric modulation of P2X3 without taste disturbance
por: Guo, Chang-Run, et al.
Publicado: (2023)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant
por: Chawla, Akshita, et al.
Publicado: (2023)

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
por: Martinez, Fernando J., et al.
Publicado: (2021)

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
por: Nussbaum, Jesse C., et al.
Publicado: (2022)

The long β2,3-sheets encoded by redundant sequences play an integral role in the channel function of P2X7 receptors
por: Ma, Xue-Fei, et al.
Publicado: (2022)

Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2021)

New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study
por: Zhang, Mengru, et al.
Publicado: (2023)

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Similarities and differences between the cough suppression test and the cough challenge test
por: Zhao, Kun, et al.
Publicado: (2023)

A randomized, double-blinded, placebo-controlled clinical trial of duloxetine hydrochloride enteric-coated tablets in the treatment of refractory chronic cough
por: Wang, Shengyuan, et al.
Publicado: (2023)

Case Report: Premature Ventricular Beats-Induced Chronic Cough and Cough Syncope
por: Hu, Yue, et al.
Publicado: (2021)

Psychological morbidity and chronic cough: which is predominant? A comparison of clinical characteristics
por: Zhang, Tongyangzi, et al.
Publicado: (2023)

Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough
por: Long, Li, et al.
Publicado: (2019)

The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial
por: Gao, Ronglin, et al.
Publicado: (2022)

Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study
por: Zhang, Mengru, et al.
Publicado: (2023)

Effect of pregabalin for the treatment of chronic refractory cough: A case report
por: Li, Jun, et al.
Publicado: (2019)

Predictive factors of cough after uniportal video-assisted thoracoscopic pulmonary resection
por: Pan, Liu-Ying, et al.
Publicado: (2020)

Nonpharmacological cough control therapy for chronic refractory cough and cough associated with underlying lung disease
por: Mohammed, Sana, et al.
Publicado: (2020)

Long-COVID severe refractory cough: discussion of a case with 6-week longitudinal cough characterization
por: Kang, Yu Ri, et al.
Publicado: (2022)

Gabapentin for Chronic Refractory Cancer Cough
por: Atreya, Shrikant, et al.
Publicado: (2016)

Management of chronic refractory cough in adults
por: Visca, Dina, et al.
Publicado: (2020)

Capsaicin-sensitive cough receptors in lower airway are responsible for cough hypersensitivity in patients with upper airway cough syndrome
por: Yu, Li, et al.
Publicado: (2013)

Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework
por: Kum, Elena, et al.
Publicado: (2021)

Evaluation methods and influencing factors of cough sensitivity
por: Mei, Hao, et al.
Publicado: (2022)

A Study on Cough Sensitivity and Airway Inflammation in Patients with Sinobronchial Syndrome
por: Wang, Shengyuan, et al.
Publicado: (2022)

Identification of CDK1 as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis
por: Qin, Si, et al.
Publicado: (2021)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Randomised trial of the P2X(3) receptor antagonist sivopixant for refractory chronic cough
por: Niimi, Akio, et al.
Publicado: (2022)

Thymopentin-Mediated Inhibition of Cancer Stem Cell Stemness Enhances the Cytotoxic Effect of Oxaliplatin on Colon Cancer Cells
por: Yu, Peng-Cheng, et al.
Publicado: (2022)

Prediction of therapeutic efficacy of gabapentin by Hull Airway Reflux Questionnaire in chronic refractory cough
por: Zhang, Mengru, et al.
Publicado: (2020)

State of the Art for Refractory Cough: Multidisciplinary Approach
por: Vertigan, Anne E.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qmga02dsh576rc4i7op0dn57sj